New brands mask a stalled eye care recovery
- PBH is a brand owner that builds revenue through marketing and shelf placement.
- Breathe Right has successfully scaled to become the largest brand in the portfolio, masking core business weakness.
- Clear Eyes supply faces renewed delays, with full year fiscal 2027 sales now expected to be under 20 million dollars.
- Dramamine is seeing unexpected growth as a remedy for nausea in users of GLP-1 medications.
- The stock depends on successful integration of the new brands while fixing the core eye care supply chain by fiscal 2028.
Buying growth while waiting on supply
The core PBH thesis is based on owning small but useful health brands that generate steady cash. People buy products like eye drops, yeast infection treatments, hydration powders, earwax removers, and sleep aids because they need them, not because they are trendy.
The main problem remains Clear Eyes. A long supply issue kept PBH from meeting demand, and the recovery timeline has been pushed out again after October production shortfalls at the Pillar5 facility. Management now expects under 20 million dollars in Clear Eyes sales for fiscal 2027, delaying any meaningful recovery to fiscal 2028.
To fill the growth void, PBH is leaning on its acquisitions. Breathe Right brings about 200 million dollars in annual revenue and is now the largest brand in the portfolio. The company is also seeing an unexpected boost in its stomach care segment, as Dramamine sales rise to help GLP-1 users manage nausea.
The bear case asks if PBH can ever run its newly acquired Pillar5 facility well enough to rebuild Clear Eyes shipments, and whether it can integrate new acquisitions without losing focus. The bull case points to the immediate scale from Breathe Right masking the near term headwinds.
Small health brands, steady cash
PBH makes money by selling over-the-counter healthcare products to retailers. Over-the-counter means products people can buy without a prescription. The company spends on marketing, packaging, product updates, and retailer relationships to keep its brands on shelves and in online carts.
This model works well because the products are low cost and needs based. A consumer with dry eyes, heartburn, dehydration, or a cold usually wants a trusted fix. PBH does not need to invent a new medicine every year to stay relevant.
The weak spot is operations. If PBH cannot make enough product, retailers cannot sell it. Clear Eyes showed how a supply chain issue can turn a steady brand into a drag on revenue. Owning Pillar5 was supposed to reduce that risk, but zero safety stock and recent production misses show PBH is still struggling to run the manufacturing side.
Capital allocation is a key part of the story. The company generates strong free cash flow, which it uses for share repurchases and strategic acquisitions like Breathe Right and LaCorium.
Where the brands fit
Eye & Ear Care
Clear Eyes is the key recovery brand, with TheraTears and Debrox also in the group. Production shortfalls have pushed recovery expectations out to fiscal 2028.
Women's Health
Monistat and Summer's Eve are important brands in this group. This category provides steady performance.
Wellness, Sleep and Other
Formed by the Breathe Right acquisition, which is now the largest brand in the portfolio, generating about 200 million dollars annually.
Gastrointestinal and Pediatric
Reliable segments offering unexpected growth tailwinds, as Dramamine benefits from nausea side effects experienced by GLP-1 users.
International
Led by Hydralyte in Australia and recently strengthened by the LaCorium Health acquisition.
Mostly North America
The mix reflects fiscal 2026 annual segment revenue before the new acquisitions. North American OTC Healthcare was 83.9 percent of revenue, with International OTC Healthcare at 16.1 percent. The new wellness and sleep category will alter this pro forma mix.
What could break the thesis
Integration of new brands
High impact · Medium oddsPBH just added significant revenue through Breathe Right and LaCorium. If management struggles to integrate these brands while also trying to fix Pillar5, overall growth could stall.
Pillar5 integration misses
High impact · High oddsPBH bought Pillar5 to control more of the Clear Eyes supply chain. Recent October production shortfalls and zero safety stock show the facility is still highly volatile.
Clear Eyes share does not come back
High impact · Medium oddsEven as supply improves, shoppers may have tried rival eye drops during the shortage. Retailers may also have given shelf space to competitors permanently.
E-commerce orders stay noisy
Medium impact · High oddsManagement has called out volatile order patterns from a major e-commerce retailer. Those orders can move quarterly sales even when consumer demand is steadier.
In one breath
What does Prestige Consumer Healthcare do?
PBH owns and sells over-the-counter healthcare brands. Its products include eye drops, women's health products, sleep aids, hydration, and stomach care.
Why does Clear Eyes matter so much for PBH?
Clear Eyes has been a major source of pressure because PBH could not make and ship enough product. The brand will generate under 20 million dollars in fiscal 2027, making its fiscal 2028 recovery a key focus.
Is PBH mainly a growth stock or a cash flow stock?
Right now it looks more like a cash flow and portfolio integration story. Growth from new acquisitions is masking the ongoing supply issues in the core eye care business.
What is the next thing investors should watch?
Watch whether the new Breathe Right brand maintains its revenue targets. The second signal is whether Clear Eyes production at Pillar5 finally stabilizes ahead of fiscal 2028.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - Specialty & Generic companies
Companies near Prestige Consumer Healthcare Inc. in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

